List of Excipients in Branded Drug ORAPRED

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	ORAPRED	prednisolone sodium phosphate	59212-700	CELLULOSE, MICROCRYSTALLINE
Advanz Pharma (US) Corp	ORAPRED	prednisolone sodium phosphate	59212-700	CITRIC ACID MONOHYDRATE
Advanz Pharma (US) Corp	ORAPRED	prednisolone sodium phosphate	59212-700	CROSPOVIDONE
Advanz Pharma (US) Corp	ORAPRED	prednisolone sodium phosphate	59212-700	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER

Orapred Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Orapred is a prednisolone sodium phosphate product historically marketed in oral solution and orally disintegrating tablet forms. Its commercial differentiation depended less on the active ingredient, which is widely available, than on taste masking, rapid oral disintegration, pediatric dosing flexibility, and excipient tolerability. The strongest current opportunities are generic or private-label pediatric formulations, preservative-optimized liquids, and orally disintegrating dosage forms with improved palatability and dose flexibility.

What is Orapred and which dosage forms were commercialized?

Orapred contains prednisolone sodium phosphate, a water-soluble corticosteroid prodrug used for inflammatory and allergic conditions. The product was developed for pediatric and other patients who have difficulty swallowing conventional tablets.

Product	Active ingredient	Primary differentiation	Commercial relevance
Orapred Oral Solution	Prednisolone sodium phosphate	Liquid dosing and pediatric administration	Competes with generic prednisolone solutions
Orapred ODT	Prednisolone sodium phosphate	Orally disintegrating tablet, no conventional swallowing required	Competes through convenience and palatability
Conventional prednisolone tablets	Prednisolone or prednisolone sodium phosphate	Low-cost solid oral dosage form	Price-driven generic competition

The ODT product was approved by the FDA under NDA 21-676. FDA labeling identifies prednisolone sodium phosphate as the active ingredient and describes the ODT as a rapidly disintegrating tablet intended to dissolve in the mouth or be dispersed in water before administration.[1]

Orapred’s commercial importance has declined as generic prednisolone sodium phosphate oral solutions and tablets have become available. The underlying active ingredient has limited composition-of-matter exclusivity value because prednisolone is an established corticosteroid. Product-level value therefore depends on formulation execution, manufacturing cost, regulatory substitutability, and prescriber or caregiver preference.

What excipients are used in Orapred formulations?

The excipient system differs materially between the oral solution and ODT products.

Orapred oral solution excipients

Prednisolone sodium phosphate is highly water soluble, allowing a liquid formulation without the solubility problems associated with prednisolone base. A typical Orapred oral solution excipient platform includes:

• Purified water
• Sweeteners such as sorbitol or sucrose
• Glycerin
• Buffering agents, including citrate salts or citric acid
• Chelating agents such as edetate disodium
• Preservatives, including sodium benzoate
• Flavoring agents
• pH-adjusting agents

The excipient strategy addresses four technical requirements:

1. Maintain prednisolone sodium phosphate in solution.
2. Control pH and chemical stability.
3. Mask corticosteroid bitterness.
4. Preserve microbiological quality during multidose use.

The formulation must also control viscosity and pourability. Excessive viscosity can impair dose measurement, increase residue in oral syringes, and reduce caregiver acceptance.

Orapred ODT excipients

The ODT platform requires a porous or rapidly wettable tablet matrix. Orapred ODT labeling identifies excipients associated with direct-compression or fast-disintegration systems, including mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, flavoring components, and the sweetener aspartame.[1]

The principal functional roles are:

Excipient function	Likely formulation objective
Mannitol	Diluent, cooling mouthfeel, improved palatability
Crospovidone	Rapid water uptake and tablet breakup
Magnesium stearate	Lubrication during compression
Colloidal silicon dioxide	Flow improvement and moisture control
Aspartame	High-intensity sweetness and taste masking
Flavor system	Reduction of bitter corticosteroid perception

The ODT must balance conflicting requirements. Higher compression force improves mechanical strength but can slow disintegration. More lubricant can improve manufacturing performance but may reduce wettability. Greater porosity accelerates disintegration but increases friability and moisture sensitivity.

How important is taste masking for Orapred commercial performance?

Taste masking is a central commercial issue for prednisolone products. Corticosteroids can produce bitterness and lingering aftertaste, particularly in pediatric oral liquids. A formulation that is pharmacokinetically equivalent but poorly accepted may experience lower adherence and greater caregiver resistance.

Orapred’s excipient strategy uses several layers of sensory control:

• High-intensity sweetener to reduce bitterness
• Mannitol for a cooling and clean mouthfeel
• Fruit or confectionery flavoring
• Rapid disintegration to minimize residence time in the mouth
• Liquid buffering to support a consistent flavor profile

The most commercially relevant taste-masking variables are not limited to sweetness. Bitter aftertaste, throat irritation, residual tablet particles, and flavor persistence can materially affect product preference.

A generic developer can pursue several strategies:

Sweetener substitution

Aspartame provides strong sweetness at low concentration but creates a labeling issue for patients with phenylketonuria because it contains phenylalanine. Alternatives include sucralose, acesulfame potassium, saccharin, sodium saccharin, or combinations of polyols and high-intensity sweeteners.

A substitution may improve labeling flexibility but can alter:

• Sweetness profile
• Aftertaste
• Tablet weight
• Moisture sensitivity
• Compression behavior
• Regulatory comparability

Flavored oral solution

A liquid generic can use a different flavor system while maintaining the same active concentration and pharmacopoeial quality. The opportunity is strongest where the product has better palatability, a lower sugar burden, or more convenient dosing.

Particle or molecular taste masking

More advanced approaches include polymer coating of drug particles, ion-exchange resins, cyclodextrin complexes, and lipid-based barriers. These approaches can improve taste but introduce development risks involving dissolution, dose uniformity, scale-up, and bioequivalence.

For prednisolone sodium phosphate, aggressive taste-masking technology may be commercially unnecessary if a simple buffered liquid or sweetened ODT achieves acceptable sensory performance at lower cost.

What formulation patents protected Orapred?

Orapred’s historical protection was primarily formulation-based rather than based on a new active pharmaceutical ingredient. Potentially relevant claim categories include:

• Orally disintegrating prednisolone sodium phosphate tablets
• Specific excipient combinations
• Rapid disintegration and dissolution profiles
• Flavor or taste-masking systems
• Pediatric liquid compositions
• Manufacturing processes for low-dose corticosteroid tablets

The commercial significance of these patents has diminished because the key product patents have reached or passed their expected expiration windows, and generic prednisolone products are widely marketed. Current freedom-to-operate analysis must be performed against the live U.S. Patent and Trademark Office record, FDA Orange Book listings, and any continuing patent family members.

Orange Book status

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with an approved drug application.[2] A product’s historical patent estate should not be treated as an active barrier without confirming:

• Whether the NDA remains listed as marketed
• Whether patents remain in the Orange Book
• Whether any patent term extension applies
• Whether listed patents have expired
• Whether a generic applicant has filed a Paragraph IV certification
• Whether litigation or settlement agreements remain operative

Orapred does not have the type of biologic exclusivity or complex-device protection associated with newer specialty products. Its main legal exposure is therefore formulation patent expiry and generic substitution.

When did Orapred lose exclusivity?

Orapred’s exclusivity profile is substantially different from that of a newly approved drug. Prednisolone has been used clinically for decades, and the commercial product’s protection depended on formulation, dosage form, and regulatory exclusivity.

The relevant timeline is:

Event	Commercial effect
FDA approval of Orapred ODT	Created branded dosage-form differentiation
Approval of generic prednisolone products	Reduced active-ingredient and price protection
Expiration of formulation patents	Lowered barriers to competing dosage forms
Generic oral solution availability	Increased substitution and reimbursement pressure
Brand discontinuation or reduced availability	Shifted demand toward generic suppliers

Because Orapred products and related prednisolone products have had multiple NDA and abbreviated new drug application histories, a single “loss of exclusivity” date is not sufficient for all presentations. ODT, oral solution, and conventional tablet products must be evaluated separately using the FDA’s current Drugs@FDA and Orange Book databases.[2,3]

What generic entry risks exist for Orapred?

Generic entry risk is high for standard oral solutions and conventional tablets. The active ingredient is established, the dosage forms are conventional, and the clinical use is well understood.

Oral solution risk

The principal generic pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence. Key competitive variables include:

• Prednisolone sodium phosphate concentration
• pH
• Preservative system
• Sugar content
• Flavor
• Bottle and syringe configuration
• Stability after opening
• Container-closure compatibility

Generic developers may avoid direct imitation of every excipient if the product remains pharmaceutically equivalent and meets FDA requirements. This creates room for differentiated formulations that reduce sugar, remove specific preservatives, or improve palatability.

ODT risk

ODT competition is more technically demanding. Developers must demonstrate:

• Rapid disintegration
• Adequate mechanical strength
• Dose uniformity
• Appropriate dissolution
• Moisture stability
• Acceptable packaging performance
• Comparable systemic exposure

An ODT can be vulnerable to manufacturing variability because low-dose drug loading, porous structure, lubrication, and tablet hardness interact closely. Packaging is also important. Moisture ingress can increase tablet softening, reduce friability performance, or alter disintegration.

Paragraph IV challenges

A Paragraph IV certification could challenge any unexpired Orange Book-listed formulation patent by asserting that the patent is invalid, unenforceable, or not infringed. For Orapred, the commercial value of such a challenge depends on whether a live patent claims a commercially relevant ODT or oral-solution formulation.

The absence of a major current litigation profile does not eliminate risk. A generic applicant can still create launch uncertainty through:

• Patent invalidity litigation
• Declaratory-judgment proceedings
• Manufacturing-process disputes
• Labeling litigation involving pediatric indications
• Contract-manufacturing or supply disputes

What commercial opportunities remain in Orapred excipients?

The most attractive opportunities are formulation improvements that create measurable patient or payer value without requiring a new clinical development program.

Preservative-reduced pediatric solution

A preservative-reduced or preservative-free presentation could target infants, children with preservative sensitivity, and institutions seeking simpler excipient profiles. The principal technical challenge is maintaining microbiological quality in a multidose package.

Commercial requirements include:

• Unit-dose packaging or a validated multidose closure
• Demonstrated in-use stability
• Controlled microbial limits
• Reliable oral-syringe compatibility
• Competitive manufacturing cost

Sugar-reduced or sugar-free liquid

A sugar-free formulation can appeal to caregivers and clinicians concerned about dental exposure, caloric load, or repeated dosing. Polyols and high-intensity sweeteners can replace sucrose, but the product must control laxation risk, osmolarity, and aftertaste.

Improved ODT taste masking

A next-generation ODT could use a non-aspartame sweetener system, improved flavor, or a coated-particle approach. The most commercially defensible positioning would be:

• Easier administration without water
• Better taste acceptance
• Lower tablet residue
• Flexible pediatric strengths
• More robust packaging

Flexible-dose granules or dispersible tablets

A dispersible tablet or oral granule could provide more accurate weight-based dosing than a liquid while reducing shipping volume and preservative requirements. The product would need a clear administration method and strong caregiver instructions.

Unit-dose hospital packaging

Emergency departments, pediatric clinics, and hospitals may value unit-dose sachets, blistered ODTs, or premeasured oral-solution devices. These formats can reduce medication errors and improve inventory control.

How does Orapred compare with competing corticosteroid formulations?

Product type	Main advantage	Main weakness	Commercial opportunity
Prednisolone oral solution	Flexible dosing	Taste, preservatives, measuring errors	Sugar-free, preservative-optimized, unit-dose formats
Prednisolone ODT	No conventional swallowing	Moisture sensitivity, higher manufacturing cost	Better taste, stronger packaging, pediatric strengths
Prednisolone tablets	Low cost and broad supply	Swallowing difficulty and dose inflexibility	Limited differentiation
Dexamethasone liquid or tablet	Potency and smaller dose volume	Different clinical use and dosing conversion	Competes in selected indications, not as a direct substitute
Methylprednisolone tablets	Established solid dosage form	Less suitable for young children	Limited pediatric substitution

Orapred’s strongest competitive position remains administration convenience. It does not have a durable advantage based on the active ingredient.

What manufacturing and IP barriers affect new Orapred products?

Manufacturing barriers are moderate rather than prohibitive. Oral solutions are relatively straightforward but require control of pH, preservative efficacy, microbial quality, and container compatibility. ODTs require greater process control.

Key manufacturing risks include:

• Low-dose content uniformity
• Powder flow during compression
• Tablet capping and friability
• Lubricant overuse
• Moisture ingress
• Flavor loss during storage
• Stability of sweeteners and preservatives
• Scale-up of taste-masking coatings

The strongest IP positions are likely to arise from narrowly defined formulation claims tied to a measurable technical result, such as rapid disintegration under specified conditions, improved stability, or a defined taste-masking composition. Broad claims covering prednisolone sodium phosphate in a liquid or tablet are more vulnerable to prior-art challenges.

Key Takeaways

• Orapred’s value was created by dosage-form and excipient design, not by a novel corticosteroid.
• The principal formulations were oral solution and orally disintegrating tablets.
• Taste masking, rapid disintegration, sweetness, flavor, and pediatric administration are the core formulation issues.
• Generic entry risk is high for conventional prednisolone products and substantial for ODTs.
• Commercial opportunities remain in preservative-optimized liquids, sugar-free formulations, non-aspartame ODTs, unit-dose packaging, and flexible-dose dispersible products.
• Any current patent conclusion requires confirmation against the live FDA Orange Book and USPTO records.
• Manufacturing complexity is moderate for oral solutions and higher for ODTs because of moisture, compression, and content-uniformity risks.
• Orapred has limited durable exclusivity because prednisolone is an established active ingredient with broad generic availability.

FAQs

Is Orapred the same as prednisolone?

Orapred contains prednisolone sodium phosphate, a water-soluble form of prednisolone. Products may differ in concentration, excipients, flavor, dosage form, and approved labeling.

Which Orapred excipient is most important for taste?

The taste profile depends on the combined sweetener, flavor, buffering, and dosage-form system. In ODT products, mannitol, high-intensity sweeteners, and flavoring agents are especially important.

Can aspartame be removed from an Orapred ODT generic?

Yes, a generic developer may use an alternative sweetener system if the product satisfies applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Is a preservative-free prednisolone solution commercially viable?

It can be viable, particularly in unit-dose or validated multidose packaging. The principal development issue is microbiological control throughout shelf life and the in-use period.

Are Orapred patents still a major barrier to generic development?

The principal barrier is unlikely to be the prednisolone active ingredient. Developers must assess any live formulation patents, Orange Book listings, regulatory exclusivity, and litigation before launch.

References

1. U.S. Food and Drug Administration. (2003). Orapred ODT (prednisolone sodium phosphate) orally disintegrating tablets, prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

4. DailyMed. (2024). Prednisolone sodium phosphate oral solution and orally disintegrating tablet labeling. National Library of Medicine.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.